Jason Ludwig, DO
Family Medicine · Meridian, IDNPI 1144258534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 404 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 404 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$828
- AbbVie$491
- Amgen$482
- Novo Nordisk$453
- Pfizer$346
- Novartis$275
- plus $4K from 54 others
What the payments were for
- Speaking & faculty fees$230%
- Food & beverage$7,35698%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,479 in reported general payments places this provider in the 95th percentile of 803 family medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 791 | $321,884 |
| OzempicSemaglutide | 66 | $68,553 |
| MounjaroTirzepatide | 56 | $68,157 |
| JardianceEmpagliflozin | 150 | $54,516 |
| MyrbetriqMirabegron | 214 | $53,485 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $42,321 |
| CreonLipase/Protease/Amylase | 38 | $40,280 |
| TrulicityDulaglutide | 26 | $35,599 |
| JanuviaSitagliptin Phosphate | 60 | $24,910 |
| XareltoRivaroxaban | 52 | $24,618 |
| RexultiBrexpiprazole | 31 | $23,919 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 239 | $19,546 |
| FarxigaDapagliflozin Propanediol | 57 | $18,650 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $17,816 |
| Atorvastatin Calcium | 1,109 | $13,398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $346 | $321,884791 claims |
| Lilly USA, LLCMounjaro, Trulicity | $95 | $103,75682 claims |
| Novo NordiskOzempic | $453 | $68,55366 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $238 | $60,846143 claims |
| Boehringer IngelheimJardiance | $114 | $54,516150 claims |
| Astellas Pharma US IncMyrbetriq | $238 | $53,485214 claims |
| AbbVieCreon, Restasis | $491 | $49,17351 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $828 | $34,61697 claims |
| MerckJanuvia | $116 | $24,91060 claims |
| Johnson & JohnsonXarelto | $207 | $24,61852 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $215 | $23,91931 claims |
| Eisai Inc.Fycompa | $117 | $13,00315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 803 family medicine providers in Idaho.
Other family medicine in Meridian
- David ButukMeridian$206K
- Timothy McHughMeridian$165K
- Mark JohnsonMeridian$10K
- Jacob SmithMeridian$7K
- Ginger AllenMeridian$6K
- George ThomasMeridian$6K
- Mark TurnerMeridian$6K
- Aaron MoorhouseMeridian$5K
- Kenneth CongerSandpoint$266K
- Anne BroadwayIdaho Falls$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.